Nuwellis Directors Stack Up Free Options as Patent Boom Sparks Insider Optimism—Could a 97% Drop Be Reversed?
Insider option buys at Nuwellis signal optimism about its new midline catheter patent, but investors face low valuation and high volatility—watch the next filings closely.
3 minutes to read